보고서 요약(국문)

개요
전 세계 특발성 저신장 치료 기기 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 보이며 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
특발성 저신장(ISS)은 질병의 소견 없이 특정 연령, 성별 및 인구 집단의 평균 키보다 2표준편차 이상 작은 키를 특징으로 하는 질환으로 정의됩니다.
특발성 저신장 아동에게 성장호르몬(GH)을 투여하면 치료 기간에 따라 3~7cm의 성인 키 증가를 유도할 수 있습니다. 특발성 저신장 아동의 경우, 다른 GH 치료 질환에서 관찰되는 부작용 프로필과 비교했을 때 GH 치료와 관련된 부작용이 적습니다.
시장 동향: 성장 동인 및 제약 요인
특발성 저신장 발병률 증가
특발성 저신장 사례 수의 증가는 시장 성장을 견인할 것으로 예상됩니다. 아로마타제 억제제(AI)는 안드로겐이 에스트로겐으로 전환되는 것을 차단하고 성장판에서 에스트로겐의 작용을 감소시키는 화합물입니다. 이러한 이유로 AI는 성장호르몬 결핍증, 특발성 저신장증, 체질적 성장 지연이 있는 남아의 키 성장에 개입하는 데 사용되어 왔습니다.
프론티어스(Frontiers) 보고서에 따르면, 많은 사람들이 저신장 진단을 받고 있으며, 그중 80%는 특발성 저신장증을 앓고 있는 것으로 추정됩니다. 따라서 환자 수의 증가는 시장 성장을 견인할 것으로 예상됩니다.
제한 요인
치료에 대한 낮은 인식
이용 가능한 치료 옵션에 대한 낮은 인식은 시장 성장을 저해할 것으로 예상됩니다. 이는 환자들이 자신의 질병을 인지하지 못하게 하여 시장 성장에 직접적인 영향을 미칠 수 있기 때문입니다. 또한, 치료 옵션이 제한적이고 치료 비용이 높은 것도 시장 성장에 영향을 미칠 수 있습니다.

시장 세분화 분석
전 세계 특발성 저신장 치료 시장은 치료 유형, 최종 사용자 및 지역별로 세분화됩니다.
성장 호르몬 치료 부문은 시장 점유율의 56.3%를 차지했습니다.
성장 호르몬 치료 부문이 시장에서 지배적인 위치를 차지하는 이유는 성장 호르몬 치료가 FDA 승인을 받은 치료법으로, 다른 치료법에 비해 안전하다고 여겨지기 때문입니다. 치료의 안전성과 효율성이 이 부문의 시장 지배력을 유지하는 요인으로 작용할 것으로 예상됩니다.
특발성 저신장으로 3~4년간 성장 호르몬 치료를 받는 아동은 최종 키가 5~10cm 정도 커집니다. 성장 호르몬 주사 치료는 성장 호르몬(GH) 결핍증 및 기타 저신장 유발 질환으로 진단받은 아동에게 처방됩니다.
성장 호르몬 치료가 필요한 성장 호르몬 결핍증을 확진하기 위해서는 먼저 여러 가지 검사를 시행해야 합니다. 이러한 검사에는 자극 검사, MRI, X선 촬영 등이 포함될 수 있습니다. 성장 호르몬 치료는 저신장과 관련된 성장 호르몬 결핍증을 치료하는 안전하고 효과적인 방법입니다.

실험실에서 생산된 성장 호르몬은 인체에서 생성되는 호르몬과 동일하여 치료 부작용을 줄여줍니다. 성장 호르몬은 피하 주사로 투여되며, 피부 표면 바로 아래의 지방 조직에 침투합니다. 따라서 이러한 요인들은 성장 호르몬 치료에 대한 수요를 증가시키고 예측 기간 동안 해당 부문의 성장을 촉진할 것으로 예상됩니다.
지역 분석
북미는 전 세계 특발성 저신장 치료 시장에서 상당한 비중을 차지할 것으로 예상됩니다.
북미는 주요 기업들의 존재, 새로운 치료법 개발을 위한 기술 발전, 그리고 많은 환자 수로 인해 시장에서 주도적인 위치를 차지할 것으로 예상됩니다.
예를 들어, 2023년 6월, 화이자(Pfizer Inc.)와 OPKO Health Inc.는 내인성 성장 호르몬 분비 부족으로 인한 성장 부전을 겪는 3세 이상 소아 환자 치료를 위해 주 1회 투여하는 인체 성장 호르몬 유사체인 NGENLA에 대해 미국 식품의약국(FDA)의 승인을 받았습니다.

임상 시험 증가와 이 지역의 새로운 치료 옵션 증가는 시장 성장을 견인하고 이 지역을 시장 지배적 위치로 유지할 것으로 예상됩니다.
COVID-19 영향 분석
COVID-19는 특발성 저신장증 시장 성장에 상당한 영향을 미쳤습니다. 이 기간 동안 제약 회사들은 COVID-19 치료제 생산에 집중했습니다. 봉쇄 조치는 의약품 제조에 필요한 원자재 공급망에 영향을 미쳤습니다. 병원 폐쇄와 환자 방문 감소 또한 시장 성장에 영향을 미쳤습니다.

시장 세분화
치료 유형별
• 약물 유형
o BBT-031
o 소마트로핀
o 소마트로핀 S
o 기타
• 치료법
o 성장 호르몬 치료
o 아로마타제 억제제 및 저용량 안드로겐 치료
최종 사용자별
• 병원
• 연구 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
주요 기업으로는 Pfizer Inc., GNH India, Ferring Pharmaceuticals Inc., Novo Nordisk, Genentech, Inc., Bolder Bio Technology, Inc., Eli Lilly and Company 등이 있으며, 이들 기업은 상당한 시장 점유율을 차지하고 있습니다.
이유는 무엇일까요? 보고서를 구매하시겠습니까?

• 치료 유형, 최종 사용자 및 지역별 전 세계 특발성 저신장 치료 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 특발성 저신장 치료 시장의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석이 담긴 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.
전 세계 특발성 저신장 치료 시장 보고서는 약 52개의 표, 56개의 그림, 174페이지로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Idiopathic Short Stature Treatment Devices Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Idiopathic short stature (ISS) is defined as a condition characterized by a height more than 2 standard deviations below the corresponding average height for a given age, sex, and population, without findings of disease.
GH administered to children with ISS induces an adult height gain of between 3 and 7 cm, depending on the duration of treatment. There are fewer adverse events associated with GH therapy in children with ISS when compared to side-effect profiles observed in other GH-treated disorders.
Market Dynamics: Drivers & Restraints
Increasing incidence of the idiopathic short stature
The increase in the number of cases of the condition is expected to drive the market growth. Aromatase inhibitors (AIs) are the compounds that block the conversion of androgens to estrogens and reduce the action of estrogens at the growth plate. For this reason, AIs have been used to intervene in height outcomes in boys with GH deficiency, idiopathic short stature, and constitutional growth delay.
According to the report published by Frontiers, it is estimated that a large number of people are undergoing a diagnosis of short stature and out of it 80% of people are estimated to suffer from idiopathic short stature condition. Thus, an increase in the patient count is expected to drive the market growth.
Restraint
Limited awareness about the treatment
Limited awareness about the available treatment options is expected to hinder the market. This is because people suffering from the condition are unaware of their disease which would directly impact the market growth. Additionally, the availability of only a few treatment options and the cost of the treatment could affect the market growth.
Segment Analysis
The global idiopathic short stature treatment market is segmented based on treatment type, end-user, and region.
Growth hormone therapy segment accounted for 56.3% of the market share
The growth hormone therapy segment holds the dominant position in the market share because Growth hormone therapy is the FDA-approved treatment procedure that is considered to be safe when compared to the other procedures. The safety and efficiency of the treatment are expected to hold the segment in the dominant position.
The child who undergoes growth hormone treatment for three to four years for idiopathic short stature will see their final height improved by two to four inches. Growth hormone injection treatment is prescribed for children who have been diagnosed with growth hormone (GH) deficiency and other conditions causing short stature.
Several other tests must be conducted first to confirm GH deficiency for which GH therapy is indicated. These tests may include stimulation tests, MRIs, and X-rays. GH treatment is a safe, effective way to treat growth hormone deficiency associated with short stature.
The growth hormone produced in the laboratory will be identical to the hormone produced by the body which reduces the side effects of the treatment. GH is given through a subcutaneous injection which enters into the fatty tissue just beneath the surface of the skin. Thus, the above factors are estimated to increase the demand for growth hormone therapy and increase the segment growth in the forecast period.
Geographical Analysis
North America is expected to hold a significant position in the global idiopathic short stature treatment market share
North America is expected to hold the dominant position in the market share due to the presence of the large major players in the region and also the increased technological advancements in developing new treatment procedures and the presence of a large patient population.
For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. received the U.S. Food and Drug Administration (FDA) approval for NGENLA which is a once-weekly, human growth hormone analog indicated for the treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.
The increase in clinical trials and the increase in the new treatment options in the region are expected to drive market growth and is expected to hold the region in the dominant position.
COVID-19 Impact Analysis
COVID-19 has shown a significant impact on the idiopathic short stature market growth. During this period, pharmaceutical companies have shifted their focus towards the manufacturing of COVID-19 medicine. The lockdown impacted the supply chain of raw materials for the manufacturing of the drugs. Hospitals have been closed and patient visit has also been reduced. Thus, it has impacted the growth of the market.
Market Segmentation
By Treatment Type
• Drug Type
o BBT-031
o Somatropin
o Somatropin S
o Others
• Therapy
o Growth Hormone Therapy
o Aromatase Inhibitors and Low-dose Androgen Therapy
By End-User
• Hospitals
• Research Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The leading companies with a significant market share include Pfizer Inc., GNH India, Ferring Pharmaceuticals Inc., Novo Nordisk, Genentech, Inc., Bolder Bio Technology, Inc. and Eli Lilly and Company among others
Why Purchase the Report?
• To visualize the global idiopathic short stature treatment market segmentation based on treatment type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of idiopathic short stature treatment with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global idiopathic short stature treatment market report would provide approximately 52 tables, 56 figures, and 174 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by End-User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing incidence of the idiopathic short stature
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Limited awareness about the treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Drug Type *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. BBT-031
7.2.4. Somatropin
7.2.5. Somatropin S
7.2.6. Others
7.3. By Therapy
7.3.1. Growth Hormone Therapy
7.3.2. Aromatase Inhibitors and Low-dose Androgen Therapy
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Research Centers
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Pfizer Inc. *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. GNH India
11.3. Ferring Pharmaceuticals Inc.
11.4. Novo Nordisk
11.5. Genentech, Inc.
11.6. Bolder Bio Technology, Inc.
11.7. Eli Lilly and Company
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4.	Key Developments, GNH India, Ferring Pharmaceuticals Inc., Novo Nordisk, Genentech, Inc., Bolder Bio Technology, Inc., Eli Lilly and Company

표 목록 (Tables)

List of Tables

Table 1 Global Idiopathic Short Stature Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Idiopathic Short Stature Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Idiopathic Short Stature Market Value, By 0, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Idiopathic Short Stature Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Idiopathic Short Stature Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Idiopathic Short Stature Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 7 Global Idiopathic Short Stature Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Idiopathic Short Stature Market Value, By End-User, 2021-2030 (US$ Million)

Table 9 Global Idiopathic Short Stature Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Idiopathic Short Stature Market Value, By Region, 2021-2030 (US$ Million)

Table 11 North America Idiopathic Short Stature Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 12 North America Idiopathic Short Stature Market Value, By End-User, 2021-2030 (US$ Million)

Table 13 North America Idiopathic Short Stature Market Value, By Country, 2021-2030 (US$ Million)

Table 14 South America Idiopathic Short Stature Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 15 South America Idiopathic Short Stature Market Value, By End-User, 2021-2030 (US$ Million)

Table 16 South America Idiopathic Short Stature Market Value, By Country, 2021-2030 (US$ Million)

Table 17 Europe Idiopathic Short Stature Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 18 Europe Idiopathic Short Stature Market Value, By End-User, 2021-2030 (US$ Million)

Table 19 Europe Idiopathic Short Stature Market Value, By Country, 2021-2030 (US$ Million)

Table 20 Asia-Pacific Idiopathic Short Stature Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 21 Asia-Pacific Idiopathic Short Stature Market Value, By End-User, 2021-2030 (US$ Million)

Table 22 Asia-Pacific Idiopathic Short Stature Market Value, By Country, 2021-2030 (US$ Million)

Table 23 Middle East & Africa Idiopathic Short Stature Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 24 Middle East & Africa Idiopathic Short Stature Market Value, By End-User, 2021-2030 (US$ Million)

Table 25 Pfizer Inc.: Overview

Table 26 Pfizer Inc.: Product Portfolio

Table 27 Pfizer Inc.: Key Developments

Table 28 GNH India: Overview

Table 29 GNH India: Product Portfolio

Table 30 GNH India: Key Developments

Table 31 Ferring Pharmaceuticals Inc.: Overview

Table 32 Ferring Pharmaceuticals Inc.: Product Portfolio

Table 33 Ferring Pharmaceuticals Inc.: Key Developments

Table 34 Novo Nordisk: Overview

Table 35 Novo Nordisk: Product Portfolio

Table 36 Novo Nordisk: Key Developments

Table 37 Genentech, Inc.: Overview

Table 38 Genentech, Inc.: Product Portfolio

Table 39 Genentech, Inc.: Key Developments

Table 40 Bolder Bio Technology, Inc.: Overview

Table 41 Bolder Bio Technology, Inc.: Product Portfolio

Table 42 Bolder Bio Technology, Inc.: Key Developments

Table 43 Eli Lilly and Company: Overview

Table 44 Eli Lilly and Company: Product Portfolio

Table 45 Eli Lilly and Company: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 2 Global Idiopathic Short Stature Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 3 Global Idiopathic Short Stature Market Share, By End-User, 2022 & 2030 (%)

Figure 4 Global Idiopathic Short Stature Market Share, By Region, 2022 & 2030 (%)

Figure 5 Global Idiopathic Short Stature Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 6 Drugs Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 7 Therapy Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 8 Global Idiopathic Short Stature Market Y-o-Y Growth, By End-User, 2022-2030 (%)

Figure 9 Hospitals End-User in Global Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 10 Research Centers End-User in Global Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 11 Others End-User in Global Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 12 Global Idiopathic Short Stature Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 13 North America Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 14 Asia-Pacific Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 15 Europe Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 16 South America Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 17 Middle East and Africa Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 18 North America Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 19 North America Idiopathic Short Stature Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 20 North America Idiopathic Short Stature Market Share, By End-User, 2022 & 2030 (%)

Figure 21 North America Idiopathic Short Stature Market Share, By Country, 2022 & 2030 (%)

Figure 22 South America Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 23 South America Idiopathic Short Stature Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 24 South America Idiopathic Short Stature Market Share, By End-User, 2022 & 2030 (%)

Figure 25 South America Idiopathic Short Stature Market Share, By Country, 2022 & 2030 (%)

Figure 26 Europe Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 27 Europe Idiopathic Short Stature Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 28 Europe Idiopathic Short Stature Market Share, By End-User, 2022 & 2030 (%)

Figure 29 Europe Idiopathic Short Stature Market Share, By Country, 2022 & 2030 (%)

Figure 30 Asia-Pacific Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 31 Asia-Pacific Idiopathic Short Stature Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 32 Asia-Pacific Idiopathic Short Stature Market Share, By End-User, 2022 & 2030 (%)

Figure 33 Asia-Pacific Idiopathic Short Stature Market Share, By Country, 2022 & 2030 (%)

Figure 34 Middle East & Africa Idiopathic Short Stature Market Value, 2021-2030 (US$ Million)

Figure 35 Middle East & Africa Idiopathic Short Stature Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 36 Middle East & Africa Idiopathic Short Stature Market Share, By End-User, 2022 & 2030 (%)

Figure 37 Pfizer Inc.: Financials

Figure 38 GNH India: Financials

Figure 39 Ferring Pharmaceuticals Inc.: Financials

Figure 40 Novo Nordisk: Financials

Figure 41 Genentech, Inc.: Financials

Figure 42 Bolder Bio Technology, Inc.: Financials

Figure 43 Eli Lilly and Company: Financial

세계 특발성 저신장 치료 시장 – 2023-2030

Global Idiopathic Short Stature Treatment Market - 2023-2030